One-year outcomes of coronary artery bypass graft surgery
versus percutaneous coronary intervention with multiple stenting
for multisystem disease: a meta-analysis of individual patient
data from randomized clinical trials
N. Mercado, W. Wijns, P. W. Serruys, U. Sigwart, M. D. Flather, R. H. Stables, W. W. O’Neill,
A. Rodriguez, P. A. Lemos, W. A. Hueb, et al
With the advent of a safe and progressively
more effective percutaneous coronary
intervention (PCI) for coronary artery
disease (CAD) as apposed to traditional
coronary artery bypass grafting (CABG),
the choice as to the best revascularization strategy for
multivessel disease patients remains today still very challenging...
Outcomes associated with drug-eluting and bare-metal stents:
a collaborative network meta-analysis
C. Stettler, S. Wandel, S. Allemann, A. Kastrati, M. C. Morice, A. Schömig, M. E. Pfisterer,
G. W. Stone, M. B. Leon, J. S. de Lezo, et al
The long-term safety of the first two polymerbased
drug-eluting stents (DES) approved by
the US Food and Drug Administration (FDA)
—a sirolimus-eluting stent and a paclitaxeleluting
stent—is a matter of intense and ongoing
debate, with some studies reporting increased rates
of death, myocardial infarction, or late stent thrombosis
compared with bare-metal stents (BMS)...
Clinical end points in coronary stent trials: a case for
standardized definitions
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G. A. van Es, P. G. Steg, M. A. Morel, L. Mauri, P. Vranckx, et al; Academic Research Consortium
For every clinical cardiologist and cardiovascular
researcher, this consensus article calling for standardized
outcome definitions in coronary stent
trials should be compulsory reading...
Stent thrombosis late after implantation of first-generation
drug-eluting stents: a cause for concern
E. Camenzind, P. G. Steg, W. Wijns
At the European Society of Cardiology (ESC)/
World Congress of Cardiology (WCC) in
Barcelona in 2006, some of us were caught
off guard by a plenary session combining
three critical presentations by Edoardo Camenzind,
Salim Yusuf, and Alain Nordmann, who raised
serious concerns about the long-term safety profile of
drug-eluting stents (DES)...
Are drug-eluting stents associated with a higher rate of late
thrombosis than bare metal stents? Late stent thrombosis:
a nuisance in both bare metal and drug-eluting stents
P. W. Serruys, J. Daemen
This position paper, intended as a point-bypoint
rebuttal to the paper by Camenzind et al,
is a thorough reanalysis of the issue of early
and late stent thrombosis (ST), starting from
the introduction of the bare-metal stent (BMS),
through the advent of brachytherapy, and finally focusing
on drug-eluting stent (DES) data...
Drug-eluting stent update 2007: Part I. A survey of current and
future generation drug-eluting stents: meaningful advances or
more of the same? Part II: Unsettled issues
J. Daemen, P. W. Serruys
Part I is a comprehensive review of the past,
present, and foreseeable future of drug-eluting
stents (DES), whose numbers keep growing in
an exponential manner...
Cyphering the complexity of coronary artery disease using the Syntax
score to predict clinical outcome in patients with three-vessel lumen
obstruction undergoing percutaneous coronary intervention
M. Valgimigli, P. W. Serruys, K. Tsuchida, S. Vaina, M. A. Morel, M. J. van den Brand,
A. Colombo, M. C. Morice, K. Dawkins, B. de Bruyne, et al; ARTS II
Since the earliest reports of coronary angiography,
the extent of coronary artery narrowing has been
considered a primary determinant of survival in
patients with coronary artery disease...
Early and late coronary stent thrombosis of sirolimus-eluting
and paclitaxel-eluting stents in routine clinical practice:
data from a large two-institutional cohort study
J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, C. Morger, N. Kukreja,
P. Jüni, G. Sianos, G. Hellige, et al
This cornerstone paper stems from the institutional
databases of two tertiary referral centers
in Europe, namely, Bern and Rotterdam...
Pathological correlates of late drug-eluting stent thrombosis:
strut coverage as a marker of endothelialization
A. V. Finn, M. Joner, G. Nakazawa, F. Kolodgie, J. Newell, M. C. John, H.K. Gold, R. Virmani
Polymer-based sirolimus- (Cypher) and paclitaxel-
eluting (Taxus) drug-eluting stents (DES)
have become a treatment of choice for patients
with symptomatic coronary artery disease undergoing
percutaneous coronary revascularization...
Balancing the risks of restenosis and stent thrombosis in
bare-metal versus drug-eluting stents. Results of a
decision analytic model
P. Garg, D. J. Cohen, T. Gaziano, L. Mauri
Decisions regarding percutaneous coronary
intervention (PCI) for obstructive coronary
disease have become increasingly challenging
for patients and physicians since the observation
of delayed stent thrombosis with
drug-eluting stents (DES)...
|
